These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 4987126)
41. Intranasal vaccination with RA 27-3 attenuated rubella virus. Puschak R; Young M; McKee TV; Plotkin SA J Pediatr; 1971 Jul; 79(1):55-60. PubMed ID: 5091268 [No Abstract] [Full Text] [Related]
42. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126 [TBL] [Abstract][Full Text] [Related]
43. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children. Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276 [TBL] [Abstract][Full Text] [Related]
44. The timing of tuberculin tests in relation to immunization with live viral vaccines. Brickman HF; Beaudry PH; Marks MI Pediatrics; 1975 Mar; 55(3):392-6. PubMed ID: 1143978 [TBL] [Abstract][Full Text] [Related]
46. Immunization of children with attenuated measles-rubella bivalent vaccine. Ramos-Alvarez M; Miller BH; Jackson JE; Schwarz AJ; Bessudo L Am J Dis Child; 1975 Apr; 129(4):474-7. PubMed ID: 1093389 [TBL] [Abstract][Full Text] [Related]
47. [Characteristics of the reactogenic properties and effectiveness of live rubella vaccine]. Iakovleva NV; Nasibov MN; Smorodintsev AA Vopr Virusol; 1969; 14(3):365-9. PubMed ID: 5820958 [No Abstract] [Full Text] [Related]
49. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Just M; Berger R; Just V Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859 [TBL] [Abstract][Full Text] [Related]
51. [Indications for possibilities of preventive vaccination against measles and rubella]. Siegert R Internist (Berl); 1971 Aug; 12(8):309-12. PubMed ID: 4936452 [No Abstract] [Full Text] [Related]
52. A field with a liver measles-mumps-rubella vaccine. Walters VW; Miller SA; Jackson JE; Kenny MT Clin Pediatr (Phila); 1975 Oct; 14(10):928-33. PubMed ID: 1100294 [TBL] [Abstract][Full Text] [Related]
53. Reinfection with rubella virus despite live vaccine induced immunity. Trials of HPV-77 and HPV-80 live rubella virus vaccines and subsequent artificial and natural challenge studies. Wilkins J; Leedom JM; Portnoy B; Salvatore MA Am J Dis Child; 1969 Aug; 118(2):275-94. PubMed ID: 5794818 [No Abstract] [Full Text] [Related]
54. Important assumptions, extrapolations, and established facts which underlie the use of live rubella virus vaccines. Leedom JM; Wilkins J; Portnoy B; Salvatore MA Am J Epidemiol; 1970 Sep; 92(3):151-7. PubMed ID: 5458941 [No Abstract] [Full Text] [Related]
56. Trials with a live attenuated rubella virus vaccine, Cendehill strain. Grant L; Belle EA; Provan G; King SD; Sigel MM J Hyg (Lond); 1970 Sep; 68(3):505-10. PubMed ID: 5272349 [TBL] [Abstract][Full Text] [Related]
57. Vaccination of infants with HPV-77 vaccine. Pavilanis V; Chagnon A; Davignon L; Joncas J Am J Dis Child; 1969 Aug; 118(2):247-51. PubMed ID: 4978509 [No Abstract] [Full Text] [Related]